Home/Filings/4/0001127602-25-007539
4//SEC Filing

Bancel Stephane 4

Accession 0001127602-25-007539

CIK 0001682852other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 4:33 PM ET

Size

8.4 KB

Accession

0001127602-25-007539

Insider Transaction Report

Form 4
Period: 2025-03-01
Bancel Stephane
DirectorChief Executive Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-03-01+357,065357,065 total
    Exercise: $30.96From: 2026-03-01Exp: 2035-03-01Common Stock (357,065 underlying)
Holdings
  • Common Stock

    5,493,897
  • Common Stock

    (indirect: See Footnote)
    6,564,880
  • Common Stock

    (indirect: See Footnote)
    9,050,372
Footnotes (3)
  • [F1]These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
  • [F2]These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
  • [F3]25% of this option will vest and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Issuer

Moderna, Inc.

CIK 0001682852

Entity typeother

Related Parties

1
  • filerCIK 0001443340

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 4:33 PM ET
Size
8.4 KB